Scope- An overview of the current opioid product market. - A brief discussion about the inconsistent prescription preferences among European physicians.- A brief profile of the most important opioid products.- A pipeline analysis of the opioid products currently in development and an overview of the developmental pipeline by phase, by the route of administration and a summary of the promising pipeline products. - An overview of the M&A and licensing deals, as well as co-development deals, across multiple indications in which opioids are frequently used in patients suffering from moderate to severe pain.
Reasons to buy
- Identify trends in the developmental pipeline for opioid analgesics. - Develop their awareness of the regulatory environment, physician concerns and inconsistency of prescription preferences among physicians.
Table of Contents1 Table of Contents 51.1 List of Tables 61.2 List of Figures 62 Introduction 72.1 Introduction 72.1.1 High Levels of Product Diversification in a Highly Competitive Market Environment 72.1.2 Inconsistent Clinician Prescribing Preferences 72.1.3 Ongoing Market Shift Towards Abuse-Resistant Product Formulations 82.1.4 Increasingly Vocal Physician Associations Raise Concerns About Extent of Opioid Abuse 92.1.5 Full Commercial Potential of Transdermal Patches May Have Yet to be Fully Exploited 93 Overview of Currently Marketed Products 103.1 Major Marketed Products 103.1.1 Oxycontin 103.1.2 Exalgo 103.1.3 Onsolis 103.1.4 Duragesic 113.1.5 Opana ER 113.1.6 Vicodin CR 113.1.7 Dolophine Hydrochloride 113.1.8 Oxecta 113.1.9 Actiq 12 3.1.10 Embeda 12 3.1.11 Kadian 12 3.1.12 Avinza 123.2 Market Drivers and Barriers 133.2.1 Drivers 143.2.2 Barriers 154 Pipeline Analysis 174.1 Introduction 174.2 Opioid Compounds in the Developmental Pipeline 204.3 Distribution by Route of Administration 234.4 Promising Pipeline Products 264.4.1 ARX-01, AcelRX Pharmaceuticals 264.4.2 ALO-02, Pfizer 264.4.3 Zohydro ER, Zogenix 264.4.4 ELI-216, Elite Pharmaceuticals 274.4.5 BEMA Buprenorphine 274.4.6 CEP-33237, Cephalon 275 Deals Analysis 285.1 Overview: 285.1.1 M&As by Year 285.1.2 M&As by Value 295.1.3 Major M&As 305.2 Licensing Agreements 335.2.1 Licensing Agreements by Year 335.2.2 Licensing Agreements by Value 345.2.3 Major Licensing Agreements 355.3 Co-Development Agreements 385.3.1 Deals by Year 385.3.2 Major Co-Development Deals 396 Appendix 406.1 Abbreviations 406.2 Bibliography 416.3 Research Methodology 416.3.1 Coverage 416.3.2 Secondary Research 426.3.3 Primary Research 426.3.4 Pipeline Analysis 426.3.5 Expert Panel Validation 426.4 Contact Us 436.5 Disclaimer 43List of TablesTable 1: Opioids Market, Global, R&D Pipeline Analysis by Phase, 2012 18 List of FiguresFigure 1: Opioids Market, Drivers and Barriers, 2012 13Figure 2: Opioids Market, Global, R&D Pipeline by Phase (%), 2012 17Figure 3: Opioids Market, Pipeline Analysis,,Opioid Compounds in Phase III 20Figure 4: Opioids Market, Pipeline Analysis,,Opioid Compounds in Phase II 21Figure 5: Opioids Market, Pipeline Analysis,,Opioid Compounds in Phase I 22Figure 6: Opioids Market, Pipeline Analysis, Route of Administration for Pipeline Molecules Currently in Phase III 23Figure 7: Opioids Market, Pipeline Analysis, Route of Administration for Pipeline Molecules Currently in Phase II 24Figure 8: Opioids Market, Pipeline Analysis, Route of Administration for Pipeline Molecules Currently in Phase I 25Figure 9: Opioids Market, M&As by Year, 2005–2012 28Figure 10: Opioids Market, M&As by Value ($m), 2005–2012 29Figure 11: Opioids Market, Licensing Agreements by Year, 2005–2012 33Figure 12: Opioids Market, Licensing Agreements by Value ($m), 2005–2012 34Figure 13: Opioids Market, Co-Development Agreements by Year, 2005–2012 38 To order this report: Drug_and_Medication Industry: Opioids Market to 2018 - Increasing Concentration of Abuse-Resistant Branded Generics Alter Competitive Dynamics in this Flat Market _________________________